PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ:STEM) today provided an update on the Company’s Phase I clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells). The trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a potential treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL). NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative condition afflicting infants and children. Enrollment and transplantation of all six patients planned for the trial has been completed.
